Inclusion Criteria:~* AD diagnosis according to NINCDS-ADRDA criteria~* Mild to moderate AD according to MMSE
14-24 inclusive~* MRI or CT assessment within 6 months before baseline, corroborating the clinical diagnosis
and excluding other potential causes of dementia especially cerebrovascular lesions~* Absence of major
depressive disease according to CSDD of less than or equal to 18~* Modified Hachinski Ischemic Scale equal to
or below 4~* Education for eight or more years~* Previous decline in cognition for more than six months as
documented in patient medical records~* A caregiver available and living in the same household or interacting
with the patient daily and available if necessary to assure administration of investigational product~*
Patients living at home or nursing home setting without continuous nursing care~* General health status
acceptable for participation in a 12-month clinical trial and ability to swallow oral medication~* No history
of treatment with rivastigmine~* For patients with either donepezil or galantamine anti-cholinesterase
inhibitor treatment prescribed, stopped treatment four weeks prior to screening~* For patients with memantine
treatment prescribed, stopped treatment four weeks prior to screening~
